Nilotinib-Induced Generalized Keratosis Pilaris: Report of a Rare Case

A 40-year-old female with chronic myeloid leukemia (CML) developed generalized keratosis pilaris (KP) after taking nilotinib, a second-generation tyrosine kinase inhibitor (TKI). The patient initially experienced localized KP after 3 months of nilotinib treatment, which resolved upon discontinuation of the drug. However, upon restarting nilotinib, she developed widespread KP within 10 days. Histopathological examination confirmed the diagnosis, and the Naranjo scale score of 11 indicated that KP was definitely induced by nilotinib. Despite the mild nature of KP, the patient continued nilotinib due to its critical role in treating CML, with the condition managed using a 10% urea-containing emollient. This case highlights the importance of recognizing and reporting rare cutaneous adverse events associated with TKIs.